Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
ST Nuotai: Ipratropium Bromide Tablets Receive Drug Registration Certificate
ST Nottai announcement: Recently, we received the “Drug Registration Certificate” for ipragliflozin tablets, duly approved and issued by the National Medical Products Administration (Certificate No.: 2026S00470). The drug name is ipragliflozin tablets; the dosage form is tablets; the specification is 50mg. The registration category is Chemical Drug Class 3, and the drug’s validity period is 18 months. The approval document number is Guo Yao Zhun Zi H20263399, valid until 2031-02-09. Both the marketing authorization holder and the manufacturer are Jiangsu Nottai Aocisino Biopharmaceutical Co., Ltd. The indication for ipragliflozin tablets is diabetic neuropathy. It is a reversible aldose reductase non-competitive inhibitor, with selective inhibition of aldose reductase.